The stock of Fluidigm Corporation (NASDAQ:FLDM) is a huge mover today! About 97,066 shares traded hands. Fluidigm Corporation (NASDAQ:FLDM) has declined 46.22% since April 5, 2016 and is downtrending. It has underperformed by 48.18% the S&P500.
The move comes after 9 months positive chart setup for the $144.48 million company. It was reported on Nov, 8 by Barchart.com. We have $10.87 PT which if reached, will make NASDAQ:FLDM worth $174.82M more.
Fluidigm Corporation (NASDAQ:FLDM) Ratings Coverage
Out of 5 analysts covering Fluidigm (NASDAQ:FLDM), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Fluidigm has been the topic of 17 analyst reports since August 7, 2015 according to StockzIntelligence Inc. As per Wednesday, August 26, the company rating was initiated by Cantor Fitzgerald. As per Thursday, August 27, the company rating was maintained by Maxim Group. The stock of Fluidigm Corporation (NASDAQ:FLDM) earned “Buy” rating by Deutsche Bank on Thursday, January 7. Mizuho maintained Fluidigm Corporation (NASDAQ:FLDM) on Sunday, August 9 with “Hold” rating. The stock of Fluidigm Corporation (NASDAQ:FLDM) earned “Buy” rating by Mizuho on Friday, August 5. The firm has “Sell” rating by Zacks given on Friday, August 21. On Friday, August 7 the stock rating was downgraded by Piper Jaffray to “Neutral”. Cowen & Co maintained it with “Outperform” rating and $13 target price in Friday, October 2 report. The firm has “Neutral” rating given on Friday, October 30 by Mizuho. Mizuho upgraded Fluidigm Corporation (NASDAQ:FLDM) on Friday, February 5 to “Buy” rating.
According to Zacks Investment Research, “Fluidigm Corporation operates as a biotech tools company that creates microfluidic-based chips and instrumentation for biological research. Products offered by the Company include BioMark HD System- a real time PCR; EP1 system for SNP genotyping; Access Array System-an Integrated Fluidic Circuit (IFC); TOPAZ system for protein crystallography; Dynamic Array integrated fluidic circuits (IFCs); and Access Array Assay Design Services. The Company’s products find its application in Gene Expression, Single-Cell Gene Expression, SNP Genotyping, Targeted Resequencing, Sample Quantitation, Copy Number Variation and Protein Crystallization. Fluidigm Corporation is based in San Francisco, California.”
Insitutional Activity: The institutional sentiment decreased to 0.82 in Q2 2016. Its down 0.14, from 0.96 in 2016Q1. The ratio dropped, as 14 funds sold all Fluidigm Corporation shares owned while 31 reduced positions. 8 funds bought stakes while 29 increased positions. They now own 25.56 million shares or 9.86% less from 28.35 million shares in 2016Q1.
Neuberger Berman Group Limited Com holds 0.01% of its portfolio in Fluidigm Corporation (NASDAQ:FLDM) for 926,340 shares. Morgan Stanley owns 1,200 shares or 0% of their US portfolio. Pnc Grp Inc Inc has invested 0% of its portfolio in Fluidigm Corporation (NASDAQ:FLDM). Polar Capital Ltd Liability Partnership accumulated 54,132 shares or 0.01% of the stock. The Pennsylvania-based Vanguard Gru has invested 0% in Fluidigm Corporation (NASDAQ:FLDM). Swiss Bank & Trust has invested 0% of its portfolio in Fluidigm Corporation (NASDAQ:FLDM). Lazard Asset Mngmt last reported 318,175 shares in the company. Thompson Mngmt owns 16,200 shares or 0.03% of their US portfolio. Geode Cap Management Ltd Llc accumulated 0% or 203,140 shares. Wasatch Advsrs last reported 1.90M shares in the company. Lord Abbett And Lc, a New Jersey-based fund reported 318,091 shares. Blackrock Management Limited Liability Co last reported 109,868 shares in the company. Alliancebernstein L P holds 41,630 shares or 0% of its portfolio. Connor Clark & Lunn Investment Management Ltd accumulated 46,775 shares or 0% of the stock. Wellington Mgmt Group Incorporated Ltd Liability Partnership holds 0% of its portfolio in Fluidigm Corporation (NASDAQ:FLDM) for 652,516 shares.
Insider Transactions: Since November 1, 2016, the stock had 2 insider buys, and 0 selling transactions for $921,102 net activity. Shares for $214,531 were bought by LEVIN CAPITAL STRATEGIES – L.P. on Tuesday, November 1.
More news for Fluidigm Corporation (NASDAQ:FLDM) were recently published by: Schaeffersresearch.com, which released: “Analyst Downgrades: Fluidigm Corporation, Netflix, Inc., and Nokia Corp” on October 13, 2016. Twst.com‘s article titled: “Fluidigm Corporation: FLUIDIGM NAMES S. CHRISTOPHER LINTHWAITE AS NEW CEO” and published on October 19, 2016 is yet another important article.
FLDM Company Profile
Fluidigm Corporation, incorporated on March 29, 2007, creates, makes and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Firm sells instruments and consumables, including integrated fluidic circuits, assays and reagents, to academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology (Ag-Bio) companies. The Firm operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. The Firm offers various types of products, which include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.